Related Experiment Videos
The clinical rationale for developing docetaxel (Taxotere)
1Department of Medicine, Institut Gustave-Roussy, Villejuif, Paris, France.
Anti-Cancer Drugs
|August 1, 1996
Summary
Resistant breast cancer is a key target for docetaxel (Taxotere). Future research will explore new uses for docetaxel based on pharmacokinetics, preclinical data, and clinical practice.
Area of Science:
- Oncology
- Pharmacology
Background:
- Resistant breast cancer is a recognized clinical challenge.
- Docetaxel (Taxotere) has shown efficacy in treating breast cancer.
Purpose of the Study:
- To explore new indications for docetaxel in resistant breast cancer.
- To establish a rationale for future docetaxel development.
Main Methods:
- Review of clinical empiricism regarding docetaxel in resistant breast cancer.
- Analysis of pharmacokinetic data.
- Evaluation of preclinical optimal combinations.
- Assessment of clinical practice patterns.
Main Results:
- Clinical experience supports docetaxel as a targeted therapy for resistant breast cancer.
- Worldwide registration of docetaxel provides opportunities for expanded indications.
- Pharmacokinetics, preclinical data, and clinical practice inform future development.
Conclusions:
- Docetaxel is a valuable agent for resistant breast cancer.
- Further development of docetaxel is warranted.
- Multifaceted evidence supports the expansion of docetaxel's therapeutic role.